| Malignant neoplasm of breast
Aromasin vs Lynparza
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Aromasin vs Lynparza with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLynparza has a higher rate of injection site reactions vs Aromasin based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Lynparza but not Aromasin, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Aromasin
Lynparza
At A Glance
Oral
Daily
Aromatase inactivator
Oral
Twice daily
PARP inhibitor
Indications
- Malignant neoplasm of breast
- Advanced breast cancer
- Carcinoma, Ovarian Epithelial
- Fallopian Tube Carcinoma
- Primary Peritoneal Cancer
- Malignant neoplasm of breast
- Adenocarcinoma of pancreas
- Hormone refractory prostate cancer
Dosing
Malignant neoplasm of breast, Advanced breast cancer 25 mg orally once daily after a meal; increase to 50 mg once daily after a meal when administered with a strong CYP 3A4 inducer.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line BRCAm maintenance) 300 mg orally twice daily; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (first-line HRD-positive, + bevacizumab) 300 mg orally twice daily with bevacizumab 15 mg/kg every 3 weeks; continue until disease progression, unacceptable toxicity, or completion of 2 years of treatment.
Carcinoma, Ovarian Epithelial, Fallopian Tube Carcinoma, Primary Peritoneal Cancer (recurrent BRCAm maintenance) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Malignant neoplasm of breast (adjuvant, gBRCAm HER2-negative high risk early) 300 mg orally twice daily for a total of 1 year, or until disease recurrence or unacceptable toxicity.
Malignant neoplasm of breast (metastatic, gBRCAm HER2-negative) 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Adenocarcinoma of pancreas 300 mg orally twice daily; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (HRR gene-mutated mCRPC, monotherapy) 300 mg orally twice daily with concurrent GnRH analog or prior bilateral orchiectomy; continue until disease progression or unacceptable toxicity.
Hormone refractory prostate cancer (BRCAm mCRPC, + abiraterone) 300 mg orally twice daily with abiraterone 1000 mg once daily and prednisone or prednisolone 5 mg twice daily; continue until disease progression or unacceptable toxicity.
Contraindications
- Known hypersensitivity to exemestane or any excipient
—
Adverse Reactions
Most common (>=10%) Hot flushes, fatigue, arthralgia, headache, insomnia, increased sweating
Serious Cardiac ischemic events (myocardial infarction, angina, myocardial ischemia), cardiac failure, clinical fractures
Postmarketing Hypersensitivity, hepatitis including cholestatic hepatitis, paresthesia, tendon disorders including tendon rupture and tendonitis and tenosynovitis, acute generalized exanthematous pustulosis, urticaria, pruritus
Most common (>=10%) nausea, fatigue, anemia, vomiting, diarrhea, decreased appetite, headache, dysgeusia, cough, neutropenia, dyspnea, dizziness, dyspepsia, leukopenia, thrombocytopenia
Serious myelodysplastic syndrome, acute myeloid leukemia, pneumonitis, venous thromboembolism, hepatotoxicity including drug-induced liver injury
Postmarketing drug-induced liver injury, hypersensitivity including angioedema, erythema nodosum, rash, dermatitis
Pharmacology
Aromatase inactivator; exemestane is an irreversible steroidal aromatase inactivator that acts as a false substrate for the aromatase enzyme, binding irreversibly to the active site ('suicide inhibition') and significantly lowering circulating estrogen concentrations in postmenopausal women without affecting adrenal corticosteroid or aldosterone biosynthesis.
Olaparib is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes (PARP1, PARP2, PARP3) involved in DNA transcription and repair; cytotoxicity occurs through inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, with enhanced activity in tumor cells harboring deficiencies in BRCA1/2, ATM, or other homologous recombination repair (HRR) genes.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Aromasin
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Lynparza
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Aromasin
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Lynparza
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (6/8)
Humana
Aromasin
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Lynparza
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Aromasin Co-Pay Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0/fillfill
Lynparza Patient Savings ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AromasinView full Aromasin profile
LynparzaView full Lynparza profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.